Century Enka's Q4 FY26 Performance

Century Enka Limited announced a 9% year-on-year increase in operating revenue for the fourth quarter of FY26, reaching ₹484 crore. For the full fiscal year FY26, operating revenue stood at ₹1,705 crore. The company also revised its operating margin guidance upwards to a range of 7% to 10%, an increase from the previous 6% to 8% outlook.

Key Financial Highlights

For the fourth quarter and full fiscal year ended March 31, 2026, Century Enka reported a 9% year-on-year rise in Q4 operating revenue to ₹484 crore. This contributed to an annual revenue of ₹1,705 crore for FY26. The company's EBITDA for Q4 FY26 was ₹55 crore, with a Net Profit After Tax (PAT) of ₹39 crore. For the full year, EBITDA stood at ₹148 crore and PAT at ₹101 crore. Additionally, the company plans significant capital expenditure (CAPEX) of over ₹100 crore for FY27.

Growth Drivers and Future Investment

Century Enka's positive revenue momentum is supported by demand in the tractor and two-wheeler segments. The company's confidence in its cost-reduction strategies, including the use of renewable energy, has led to the upward revision in margin guidance. The planned CAPEX for FY27 signals a commitment to expansion, focusing on value-added products to drive long-term growth and operational efficiency.

Navigating Market Challenges

In recent periods, Century Enka has managed market dynamics such as fluctuating raw material prices and import competition. The company's strategies have centered on efficiency initiatives and targeting segments with stable demand. The current financial performance reflects the successful implementation of these strategies, contributing to an improved outlook.

Investor Focus and Strategy

With the revised margin guidance and planned CAPEX, Century Enka appears focused on investing in growth opportunities and enhancing operations. Management responses suggest a priority on long-term value creation rather than short-term capital returns like dividends or buybacks.

Potential Risks

Investors should be aware of potential risks, including volatility in raw material prices, particularly caprolactam, which could impact short-term margins. Persistent low-priced imports also pose a competitive threat that could affect revenue realizations if import protective measures are delayed or insufficient.

Key Metrics

• Q4 FY26 Operating Revenue: ₹484 crore (9% YoY growth)
• FY26 Operating Revenue: ₹1,705 crore
• Q4 FY26 PAT: ₹39 crore
• FY26 PAT: ₹101 crore
• FY27 Planned CAPEX: Over ₹100 crore
• Revised Operating Margin Guidance: 7% - 10%

Next Steps for Investors

Investors are advised to closely monitor how the company manages raw material cost fluctuations and the impact of import competition. Tracking the progress of the planned CAPEX and the contribution of value-added products to future revenue will be crucial for assessing the company's ongoing performance.